AbCellera Biologics Inc. Receivables, Net, Current
AbCellera Biologics Inc. (ABCL) had Receivables, Net, Current of $38.42 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:ReceivablesNetCurrent · last filed 2026-08-05
- 2026-06-30: Receivables, Net, Current $38.42M.
- 2026-03-31: Receivables, Net, Current $39.16M.
- 2025-12-31: Receivables, Net, Current $39.41M.
- 2025-09-30: Receivables, Net, Current $71.25M.
| Period end | Receivables, Net, Current |
|---|---|
| 2026-06-30 | $38.42M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $39.16M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $39.41M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $71.25M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $70.00M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $63.61M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $31.98M 10-K · filed 2026-02-24 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |